drugset / Trial / NCT06924606
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2026-06-26
- Completion
- 2026-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | JS207 | Monoclonal antibody | 10 mg/kg | — |
| Subject | Tifcemalimab | Monoclonal antibody | 200 mg | — |